CrossRef enabled

PAC Archives

Archive →

Pure Appl. Chem., 2013, Vol. 85, No. 8, pp. 1725-1758

http://dx.doi.org/10.1351/PAC-REC-12-11-23

Published online 2013-07-29

CHEMISTRY AND HUMAN HEALTH DIVISION

Glossary of terms used in medicinal chemistry. Part II (IUPAC Recommendations 2013)

Derek R. Buckle1*, Paul W. Erhardt2, C. Robin Ganellin3, Toshi Kobayashi4, Thomas J. Perun5, John Proudfoot6 and Joerg Senn-Bilfinger7

1 DRB Associates, 18 Hillfield Road, Redhill, Surrey, RH1 4AP, UK
2 University of Toledo, College of Pharmacy, Center for Drug Design and Development, 2801 West Bancroft Street, Toledo, OH 43606-3390, USA
3 Department of Chemistry, Christopher Ingold Laboratory, University College London, 20 Gordon Street, London, WC1H 0AJ, UK
4 PhRMA, 4th Floor, Landic II Toranomon Building, 3-7-8 Minato-ku, 105-000 Japan
5 47731 Old Houston Highway, Hempstead, TX 77445, USA
6 Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877, USA
7 Altana Pharma AG, Byk-Gulden Str. 2, D-78467 Konstanz, Germany

References

  • 1. C. G. Wermuth, C. R. Ganellin, P. Lindberg, L. A. Mitscher. Pure Appl. Chem. 70, 1129 (1998). (http://dx.doi.org/10.1351/pac199870051129)
  • 2. IUPAC. Compendium of Chemical Terminology, 2nd ed. (the “Gold Book”). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). XML on-line corrected version: (2006–) created by M. Nic, J. Jirat, B. Kosata; updates compiled by A. Jenkins. (http://dx.doi.org/10.1351/goldbook)
  • 3. J. Fischer, C. R. Ganellin (Eds.). Analogue-based Drug Discovery, Wiley-VCH, Weinheim (2006).
  • 4. M. Dean, Y. Hamon, G. Chimini. J. Lipid Res. 42, 1007 (2001).
  • 5. G. Bringmann, A. J. P. Mortimer, P. A. Keller, M. J. Gresser, J. Garner, M. Breuning. Angew. Chem., Int. Ed. 44, 5384 (2005). (http://dx.doi.org/10.1002/anie.200462661)
  • 6. M. W. Sinz. Ann. Rep. Med. Chem. 43, 405 (2008). (http://dx.doi.org/10.1016/S0065-7743(08)00023-7)
  • 7. R. Ng. Drugs from Discovery to Approval, Wiley-Blackwell (2009).
  • 8. J. Kelder, P. D. J. Grootenhuis, D. M. Bayada, L. P. C. Delbressine, J. P. Ploemen. Pharm. Res. 16, 1514 (1999). (http://dx.doi.org/10.1023/A:1015040217741)
  • 9. S. A. Hitchcock, L. D. Pennington. J. Med. Chem. 49, 7559 (2006). (http://dx.doi.org/10.1021/jm060642i)
  • 10. M. Nordberg, J. H. Duffus, D. M. Templeton. Pure Appl. Chem. 79, 1583 (2007). (http://dx.doi.org/10.1351/pac200779091583)
  • 11. T. P. Begley. Nat. Chem. Biol. 1, 236 (2005). (http://dx.doi.org/10.1038/nchembio1005-236)
  • 12. Pubchem; http://pubchem.ncbi.nlm.nih.gov/.
  • 13. F. K. Brown. Ann. Rep. Med. Chem. 33, 375 (1998). (http://dx.doi.org/10.1016/S0065-7743(08)61100-8)
  • 14. H. Kubinyi. Chemogenomics in Drug Discovery, www.kubinyi.de/schering58-2006.pdf.
  • 15. K. G. Carson, B. D. Jaffee, G. C. B. Harriman. Ann. Rep. Med. Chem. 39, 149 (2004). (http://dx.doi.org/10.1016/S0065-7743(04)39012-3)
  • 16. G. M. Downs, P. Willett, W. Fisanick. J. Chem. Inf. Comput. Sci. 34, 1094 (1994).
  • 17. R. D. Brown, Y. C. Martin. J. Chem. Inf. Comput. Sci. 36, 572 (1996).
  • 18. D. Gorse, A. Rees, M. Kaczorek, R. Lahana. Drug Discovery Today 4, 257 (1999). (http://dx.doi.org/10.1016/S1359-6446(99)01334-3)
  • 19. W. M. Lau, A. W. White, S. J. Gallagher, M. Donaldson, G. McNaughton, C. M. Heard. Curr. Pharm. Des. 14, 794 (2008). (http://dx.doi.org/10.2174/138161208784007653)
  • 20. F. W. Schueller. Chemobiodynamics and Drug Design, p. 405, McGraw-Hill, The Blakiston Division (1960).
  • 21. C. G. Wermuth. Drug Discovery Today 11, 348 (2006). (http://dx.doi.org/10.1016/j.drudis.2006.02.006)
  • 22. J. Owens. Nat. Rev. Drug Discovery 6, 187 (2007). (http://dx.doi.org/10.1038/nrd2275)
  • 23. A. C. Cheng, R. G. Coleman, K. T. Smyth, Q. Cao, P. Soulard, D. R. Caffrey, A. C. Salzberg, E. S. Huang. Nat. Biotech. 25, 71 (2007). (http://dx.doi.org/10.1038/nbt1273)
  • 24. T. L. Doan, M. Pollastri, M. A. Walters, G. I. Georg. Ann. Rep. Med. Chem. 46, 385 (2011). (http://dx.doi.org/10.1016/B978-0-12-386009-5.00004-7)
  • 25. J. Proudfoot, O. Nosjean, J. Blanchard, J. Wang, D. Besson, D. Crankshaw, G. Gauglitz, R. Hertzberg, C. Homon, L. Llewellyn, R. Neubig, L. Walker, P. Villa. Pure Appl. Chem. 83, 1129 (2011). (http://dx.doi.org/10.1351/PAC-REC-09-05-03)
  • 26. J. H. Duffus, M. Nordberg, D. M. Templeton Pure Appl. Chem. 79, 1153 (2007). (http://dx.doi.org/10.1351/pac200779071153)
  • 27. K. J. Box, J. E. Comer. Curr. Drug Metab. 9, 869 (2008). (http://dx.doi.org/10.2174/138920008786485155)
  • 28. K. J. Box, J. E. Comer, T. Gravestock, M. Stuart. Chem. Biodivers. 6, 1767 (2009). (http://dx.doi.org/10.1002/cbdv.200900164)
  • 29. H. Gamsjäger, J. W. Lorimer, P. Scharlin, D. G. Shaw. Pure Appl. Chem. 80, 233 (2008). (http://dx.doi.org/10.1351/pac200880020233)
  • 30. S. D. Pickett, C. Luttmann, V. Guerin, A. Laoui, E. James. J. Chem. Inf. Comput. Sci. 38, 144 (1998).
  • 31. M. J. McGregor, S. M. Muskal. J. Chem. Inf. Comput. Sci. 39, 569 (1999).
  • 32. H. Zhao, Z. Guo. Drug Discovery Today 14, 516 (2009). (http://dx.doi.org/10.1016/j.drudis.2009.02.008)
  • 33. J. A. Di Massi, L. A. Faden. Nat. Rev. Drug Discovery 10, 23 (2011). (http://dx.doi.org/10.1038/nrd3296)
  • 34. M. Congreve, C. W. Murray, R. Carr, D. C. Rees. Ann. Rep. Med. Chem. 42, 431 (2007). (http://dx.doi.org/10.1016/S0065-7743(07)42028-0)
  • 35. J. B. Baell, G. A. Holloway. J. Med. Chem. 53, 2719 (2010). (http://dx.doi.org/10.1021/jm901137j)
  • 36. Medicines and Healthcare Products Regulatory Agency. Good Laboratory Practice: Background and Structure, http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/ GoodLaboratoryPractice/Structure/index.htm.
  • 37. Medicines and Healthcare Products Regulatory Agency. Good Manufacturing Practice, http://www.mhra.gov.uk / Howweregulate /Medicines/Inspectionandstandards/GoodManufacturingPractice/index.htm.
  • 38. IUPAC Green Chemistry Directory. http://www.incaweb.org/transit/iupacgcdir/overview.htm.
  • 39. R. F. Rekker. Hydrophobic Fragmental Constant (Pharmacochemistry library), Elsevier Scientific (1977).
  • 40. The IUPAC International Chemical Identifier (InChI); http://IUPAC.org/inchi/.
  • 41. Solubility definitions; http://sirius-analytical.com; Application note 08/12.
  • 42. A. L. Hopkins, C. R. Groom, A. Alex. Drug Discovery Today 9, 430 (2004). (http://dx.doi.org/10.1016/S1359-6446(04)03069-7)
  • 43. P. D. Leeson, B. Springthorpe. Nat. Rev. Drug Discovery 6, 881 (2007). (http://dx.doi.org/10.1038/nrd2445)
  • 44. B. G. Katzung. In Basic and Clinical Pharmacology, 9th ed., Lang Medical Books, McGraw-Hill (2004).
  • 45. K. A. Loomis, G. J. Brock. Ann. Rep. Med. Chem. 46, 351 (2011). (http://dx.doi.org/10.1016/B978-0-12-386009-5.00006-0)
  • 46. H. van de Waterbeemd, B. Testa. Adv. Drug Res. 16, 85 (1987).
  • 47. H. van de Waterbeemd, R. E. Carter, G. Grassy, H. Kubiny, Y. C. Martin, M. S. Tute, P. Willett. Pure Appl. Chem. 69, 1137 (1997). (http://dx.doi.org/10.1351/pac199769051137)
  • 48. Chronic Lymphocytic Leukemia Research Consortium Glossary. http://cll.ucsd.edu/glossary/ glossary_m.html.
  • 49. T. T. Wager, Xinjun Hou, P. R. Verhoest, A. Villalobos. ACS Chem. Neurosci. 1, 435 (2010). (http://dx.doi.org/10.1021/cn100008c)
  • 50. G. W. Bemis, M. A. Murcko. J. Med. Chem. 39, 2887 (1996). (http://dx.doi.org/10.1021/jm9602928)
  • 51. Australian Academy of Science. Good Prospects Ahead for Data Mining, http://www.science.org.au/nova/050/050glo.htm.
  • 52. U.S. Food and Drug Administration home page. http://www.fda.gov.
  • 53. NIH Center for Macromolecular Modeling and Bioinformatics. Nuclear Hormone Receptors, http://www.ks.uiuc.edu/Research/pro_DNA/ster_horm_rec/.
  • 54. D. Maclean, J. J. Baldwin, V. T. Ivanov, Y. Kato, A. Shaw, P. Schneider, E. M. Gordon. Pure Appl. Chem. 71, 2349 (1999). (http://dx.doi.org/10.1351/pac199971122349)
  • 55. S. C. Smith. In Analogue-based Drug Discovery II, J. Fischer, C. R. Ganellin (Eds.), p. 83, Wiley-VCH, Weinheim (2010).
  • 56. W. J. Egan. Ann. Rep. Med. Chem. 42, 449 (2007). (http://dx.doi.org/10.1016/S0065-7743(07)42029-2)
  • 57. National Center for Biotechnology Information. Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources. http://www.ncbi.nlm.nih.gov/About/primer/pharm.html.
  • 58. J. Kotz. SciBX 5 (15) (2012); (http://dx.doi.org/10.1038/scibx.2012.380)
  • 59. J. Kelder, P. D. J. Grootenhuis, D. M. Bayada, L. P. C. Delbressine, J.-P. Ploemen. Pharmaceutical Res. 16, 1514 (1999). (http://dx.doi.org/10.1023/A:1015040217741)
  • 60. D. J. W. Grant. “Theory and origin of polymorphism”, in Polymorphism in Pharmaceutical Solids, H. G. Brittain (Ed.), pp. 1–34, Marcel Dekker, New York (1999).
  • 61. B. E. Evans, K. E. Rittle, M. G. Bock, R. M. DiPardo, R. M. Freidinger, W. L. Whitter, G. F. Lundell, D. F. Veber, P. S. Anderson, R. S. Chang. J. Med. Chem. 31, 2235 (1988). (http://dx.doi.org/10.1021/jm00120a002)
  • 62. Worldwide Protein Databank. http://www.wwpdb.org.
  • 63. B. Fermini, A. F. Fossa. Ann. Rep. Med. Chem. 39, 323 (2004). (http://dx.doi.org/10.1016/S0065-7743(04)39024-X)
  • 64. C. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney. Adv. Drug. Deliv. Res. 23, 3 (1997). (http://dx.doi.org/10.1016/S0169-409X(96)00423-1)
  • 65. D. C. Rees, M. Congreve, C. W. Murray, R. Carr. Nat. Rev. 3, 660 (2004).
  • 66. H.-J. Böhm, A. Flohr, M. Stahl. Drug Discovery Today: Technologies 1, 217 (2004). (http://dx.doi.org/10.1016/j.ddtec.2004.10.009)
  • 67. B.-M. Shamoon, C. Reinhard. Ann. Rep. Med. Chem. 38, 261 (2003). (http://dx.doi.org/10.1016/S0065-7743(03)38027-3)
  • 68. Daylight Chemical Information Systems home page. http://www.daylight.com.
  • 69. B. Gomes, D. de Graaf. Ann. Rep. Med. Chem. 42, 393 (2007). (http://dx.doi.org/10.1016/S0065-7743(07)42025-5)
  • 70. G. L. Patrick, Organic Chemistry Instant Notes Series. Chemistry Series, 2nd ed., Taylor & Francis Routledge, London (2004).
  • 71. R. P. Sheridan, S. K. Kearsley. J. Chem. Inf. Comput. Sci. 35, 310 (1995).